<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01004198</url>
  </required_header>
  <id_info>
    <org_study_id>TRA-204</org_study_id>
    <nct_id>NCT01004198</nct_id>
  </id_info>
  <brief_title>Phase IIa Study of MP4OX in Traumatic Hemorrhagic Shock Patients</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Controlled Dose-finding Study to Evaluate the Safety and Efficacy of MP4OX Treatment Plus Standard of Care in Severely Injured Trauma Patients With Lactic Acidosis Due to Hemorrhagic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sangart</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sangart</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      MP4OX is a novel oxygen therapeutic agent specifically developed to perfuse and oxygenate
      tissue at risk for ischemia and hypoxia. MP4OX is a pegylated hemoglobin-based colloid and
      and as a result of its molecular size and unique oxygen dissociation characteristics, targets
      oxygen delivery to ischemic tissues by selectively off-loading oxygen in tissues predisposed
      to low oxygen tension. Sangart is currently evaluating MP4OX to reduce organ dysfunction and
      failure in trauma patients with lactic acidosis due to severe hemorrhagic shock.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute traumatic injury, including both blunt and penetrating injury, is often associated with
      severe bleeding which can lead to hemorrhagic shock. During shock, inadequate perfusion of
      critical organs can lead to local ischemia and tissue hypoxia (insufficient oxygenation),
      which can be detected by an increase in serum lactate levels. Despite optimal care, more than
      10% of trauma victims who reach hospital alive will die, and many will suffer from organ
      failure. Death and significant, persistent morbidity are consequences of trauma, and
      traumatic injuries are associated with lost productivity, reduced quality of life, and direct
      costs to patients and health care systems worldwide. Current therapies, which also include
      blood transfusion, are aimed at supporting failing organs, but a therapeutic agent that could
      help to quickly restore adequate oxygenation may be beneficial to prevent or shorten duration
      of organ failure and improve patient outcome.

      Direct support for the proposed clinical application to use MP4OX in resuscitation from
      hemorrhage is found in preclinical animal studies. Using a pig model of uncontrolled
      hemorrhage and resuscitation, survival was greater and restoration of hemodynamics and
      acid-base status were improved with MP4OX relative to an equivalent volume of crystalloid,
      pentastarch, or unmodified hemoglobin. Administration of MP4OX improved 24-hour survival,
      stabilized cardiac output and arterial pressure at nearly normal levels, and reduced lactate
      levels more effectively than the control fluids. Importantly, these benefits of MP4OX were
      observed with or without co-administration of autologous blood, suggesting that blood alone
      was not sufficient to achieve complete resuscitation, and that the effects of MP4OX appear to
      be additional to those of blood.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum lactate clearance</measure>
    <time_frame>2 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free days</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU-free days</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital-free days</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sepsis-related Organ Failure Assessment (SOFA) score</measure>
    <time_frame>Daily</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Denver score</measure>
    <time_frame>Daily</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite endpoint of Time to Complete Organ Failure Resolution (CTCOFR)</measure>
    <time_frame>At 14 and 21 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Shock, Hemorrhagic</condition>
  <condition>Shock, Traumatic</condition>
  <condition>Acidosis, Lactic</condition>
  <arm_group>
    <arm_group_label>MP4OX - 250</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>250 mL dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MP4OX - 500</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mL dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ringers Lactate solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>500 mL dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MP4OX</intervention_name>
    <description>4.3 g/dL PEG-Hb solution in lactated electrolyte solution</description>
    <arm_group_label>MP4OX - 250</arm_group_label>
    <other_name>MP4</other_name>
    <other_name>MalPEG-Hb</other_name>
    <other_name>PEG-Hb</other_name>
    <other_name>Pegylated-Hb</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MP4OX</intervention_name>
    <description>4.3 g/dL PEG-Hb solution in lactated electrolyte solution</description>
    <arm_group_label>MP4OX - 500</arm_group_label>
    <other_name>MP4</other_name>
    <other_name>MalPEG-Hb</other_name>
    <other_name>PEG-Hb</other_name>
    <other_name>Pegylated-Hb</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ringers Lactate solution</intervention_name>
    <description>Ringers Lactate solution for Injection</description>
    <arm_group_label>Ringers Lactate solution</arm_group_label>
    <other_name>Lactated Ringers</other_name>
    <other_name>Hartmann's solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult male or female (surgically sterile or post-menopausal or confirmed not to be
             pregnant)

          -  Trauma injury (blunt and/or penetrating) resulting in lactic acidosis due to
             hemorrhagic shock (blood lactate level ≥ 5 mmol/L; equivalent to ≥ 45 mg/dL)

          -  Informed consent obtained before any study-related activities

        Exclusion Criteria:

          -  Not expected to survive 24 hours after randomization

          -  Evidence of severe traumatic brain injury as defined by any one of the following:
             Known non-survivable head injury or open brain injury; Glasgow Coma Score (GCS) = 3, 4
             or 5, or known AIS = 5 if GCS &gt; 5; Immediate open intracranial operation; Abnormal
             physical exam indicative of severe CNS or spinal injury

          -  Significant ongoing uncontrolled hemorrhage where control of bleeding is not expected
             within 2 hours of randomization

          -  Cardiac arrest prior to dosing

          -  Estimated time from injury to dosing &gt; 4 hours

          -  Estimated time from hospital admission to randomization &gt; 2 hours

          -  Known or suspected pregnancy (confirmed by urine test)

          -  Previous participation in this study

          -  Professional or ancillary personnel involved with this study

          -  Receipt of any investigational drug(s) within 30 days prior to study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karim Brohi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Royal London Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier de Bicêtre</name>
      <address>
        <city>Le Kremlin Bicetre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille - Hôpital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Campus Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann-Wolfgang-Goethe-Universität</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Netcare Union Hospital</name>
      <address>
        <city>Alberton</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlotte Maxeke Johannesburg Hospital</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Netcare Milpark Hospital</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Netcare Unitas Hospital, Centurian</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Steve Biko Academic Hospital</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chris Hani Baragwanath Hospital</name>
      <address>
        <city>Soweto</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal London Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>South Africa</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.sangart.com</url>
    <description>www.Sangart.com</description>
  </link>
  <reference>
    <citation>Olofsson C, Ahl T, Johansson T, Larsson S, Nellgård P, Ponzer S, Fagrell B, Przybelski R, Keipert P, Winslow N, Winslow RM. A multicenter clinical study of the safety and activity of maleimide-polyethylene glycol-modified Hemoglobin (Hemospan) in patients undergoing major orthopedic surgery. Anesthesiology. 2006 Dec;105(6):1153-63.</citation>
    <PMID>17122578</PMID>
  </reference>
  <reference>
    <citation>Olofsson C, Nygårds EB, Ponzer S, Fagrell B, Przybelski R, Keipert PE, Winslow N, Winslow RM. A randomized, single-blind, increasing dose safety trial of an oxygen-carrying plasma expander (Hemospan) administered to orthopaedic surgery patients with spinal anaesthesia. Transfus Med. 2008 Feb;18(1):28-39. doi: 10.1111/j.1365-3148.2007.00811.x.</citation>
    <PMID>18279190</PMID>
  </reference>
  <reference>
    <citation>Young MA, Lohman J, Malavalli A, Vandegriff KD, Winslow RM. Hemospan improves outcome in a model of perioperative hemodilution and blood loss in the rat: comparison with hydroxyethyl starch. J Cardiothorac Vasc Anesth. 2009 Jun;23(3):339-47. doi: 10.1053/j.jvca.2008.08.006. Epub 2008 Oct 22.</citation>
    <PMID>18948027</PMID>
  </reference>
  <reference>
    <citation>Young MA, Riddez L, Kjellström BT, Winslow RM. Effect of maleimide-polyethylene glycol hemoglobin (MP4) on hemodynamics and acid-base status after uncontrolled hemorrhage in anesthetized swine: comparison with crystalloid and blood. J Trauma. 2007 Dec;63(6):1234-44. doi: 10.1097/TA.0b013e31815bd7b0.</citation>
    <PMID>18212644</PMID>
  </reference>
  <reference>
    <citation>Young MA, Riddez L, Kjellström BT, Bursell J, Winslow F, Lohman J, Winslow RM. MalPEG-hemoglobin (MP4) improves hemodynamics, acid-base status, and survival after uncontrolled hemorrhage in anesthetized swine. Crit Care Med. 2005 Aug;33(8):1794-804.</citation>
    <PMID>16096458</PMID>
  </reference>
  <reference>
    <citation>Drobin D, Kjellstrom BT, Malm E, Malavalli A, Lohman J, Vandegriff KD, Young MA, Winslow RM. Hemodynamic response and oxygen transport in pigs resuscitated with maleimide-polyethylene glycol-modified hemoglobin (MP4). J Appl Physiol (1985). 2004 May;96(5):1843-53. Epub 2004 Jan 16.</citation>
    <PMID>14729723</PMID>
  </reference>
  <reference>
    <citation>Vandegriff KD, Winslow RM. Hemospan: design principles for a new class of oxygen therapeutic. Artif Organs. 2009 Feb;33(2):133-8. doi: 10.1111/j.1525-1594.2008.00697.x.</citation>
    <PMID>19178457</PMID>
  </reference>
  <reference>
    <citation>Vandegriff KD, Malavalli A, Mkrtchyan GM, Spann SN, Baker DA, Winslow RM. Sites of modification of hemospan, a poly(ethylene glycol)-modified human hemoglobin for use as an oxygen therapeutic. Bioconjug Chem. 2008 Nov 19;19(11):2163-70. doi: 10.1021/bc8002666.</citation>
    <PMID>18837531</PMID>
  </reference>
  <reference>
    <citation>Tsai AG, Cabrales P, Manjula BN, Acharya SA, Winslow RM, Intaglietta M. Dissociation of local nitric oxide concentration and vasoconstriction in the presence of cell-free hemoglobin oxygen carriers. Blood. 2006 Nov 15;108(10):3603-10. Epub 2006 Jul 20.</citation>
    <PMID>16857991</PMID>
  </reference>
  <reference>
    <citation>van der Linden P, Gazdzik TS, Jahoda D, Heylen RJ, Skowronski JC, Pellar D, Kofranek I, Górecki AZ, Fagrell B, Keipert PE, Hardiman YJ, Levy H; 6090 Study Investigators. A double-blind, randomized, multicenter study of MP4OX for treatment of perioperative hypotension in patients undergoing primary hip arthroplasty under spinal anesthesia. Anesth Analg. 2011 Apr;112(4):759-73. doi: 10.1213/ANE.0b013e31820c7b5f. Epub 2011 Feb 11.</citation>
    <PMID>21317165</PMID>
  </reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2009</study_first_submitted>
  <study_first_submitted_qc>October 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2009</study_first_posted>
  <last_update_submitted>August 15, 2013</last_update_submitted>
  <last_update_submitted_qc>August 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Trauma</keyword>
  <keyword>Hemorrhage</keyword>
  <keyword>Hemorrhagic shock</keyword>
  <keyword>Lactic acidosis</keyword>
  <keyword>Oxygen carriers</keyword>
  <keyword>Oxygen therapeutics</keyword>
  <keyword>Hemoglobin solutions</keyword>
  <keyword>Hemoglobin substitutes</keyword>
  <keyword>Red cell substitutes</keyword>
  <keyword>PEG-hemoglobin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Acidosis</mesh_term>
    <mesh_term>Shock, Hemorrhagic</mesh_term>
    <mesh_term>Acidosis, Lactic</mesh_term>
    <mesh_term>Shock, Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

